← Oncology Approval Tracker

FDA DECISION ·

Sarclisa + VRd

isatuximab-irfc with bortezomib, lenalidomide and dexamethasone · Sanofi

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant; use with bortezomib, lenalidomide and dexamethasone.

LAMPGEN ANALYSIS

Why it matters

The anti-CD38 antibody joins a frontline triplet for transplant-ineligible patients, distinct from transplant-eligible induction regimens.

What research teams should watch

Document transplant eligibility and prearrange blood-bank communication because anti-CD38 therapy can interfere with compatibility testing.

PRIMARY RECORDS

Sources